Payment overview · 2025
General Payments
$106.49
5 reported records · 3 companies
Healthcare provider profile · identity verified
Wei Ye, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · FLUSHING, NY · NPI 1962678458
Verified facts
What the public records show
CMS Open Payments records show Wei Ye, D.O. received $106.49 in general payments during 2025 across 5 reported records.
ABBVIE INC. accounted for 58.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $62.22 | 58.4% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.14 | 22.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.13 | 18.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $106.49 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $62.22 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
34 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 162 |
| Vascepa | Icosapent Ethyl | 566 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 522 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 469 | 116 |
| Losartan Potassium | Losartan Potassium | 402 | 112 |
| Metformin Hcl | Metformin Hcl | 375 | 94 |
| Diclofenac Epolamine | Diclofenac Epolamine | 318 | 72 |
| Ammonium Lactate | Ammonium Lactate | 307 | 86 |
| Omeprazole | Omeprazole | 291 | 79 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 284 | 63 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 247 | 87 |
| Metoprolol Succinate | Metoprolol Succinate | 191 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 50 |
| Alendronate Sodium | Alendronate Sodium | 178 | 41 |
| Meloxicam | Meloxicam | 173 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 42 |
| Simvastatin | Simvastatin | 161 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 29 |
| Mupirocin | Mupirocin | 123 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 115 | 36 |
| Ketoconazole | Ketoconazole | 113 | 26 |
| Tradjenta | Linagliptin | 113 | 25 |
| Azelastine Hcl | Azelastine Hcl | 111 | 29 |
| Famotidine | Famotidine | 103 | 30 |
| Jardiance | Empagliflozin | 103 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 36 |
| Trazodone Hcl | Trazodone Hcl | 100 | 23 |
| Montelukast Sodium | Montelukast Sodium | 86 | 28 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 85 | 23 |
| Azithromycin | Azithromycin | 83 | 73 |
| Donepezil Hcl | Donepezil Hcl | 83 | 21 |
| Meclizine Hcl | Meclizine Hcl | 82 | 53 |
| Finasteride | Finasteride | 79 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 76 | 76 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 73 | 19 |
| Hydrocortisone | Hydrocortisone | 73 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 21 |
| Raloxifene Hcl | Raloxifene Hcl | 70 | 25 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 69 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 65 | 16 |
| Atenolol | Atenolol | 63 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 19 |
| Procto-Med Hc | Hydrocortisone | 57 | 12 |
| Januvia | Sitagliptin Phosphate | 56 | 13 |
| Allopurinol | Allopurinol | 55 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 49 | 19 |
| Rybelsus | Semaglutide | 49 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 25 |
| Carvedilol | Carvedilol | 46 | 12 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | suppressed |
| Lisinopril | Lisinopril | 44 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 43 | suppressed |
| Lidocaine | Lidocaine | 43 | 12 |
| Spironolactone | Spironolactone | 43 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 24 |
| Glipizide Er | Glipizide | 39 | 11 |
| Amoxicillin | Amoxicillin | 37 | 29 |
| Folic Acid | Folic Acid | 37 | 12 |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Celecoxib | Celecoxib | 34 | 17 |
| Gabapentin | Gabapentin | 34 | 19 |
| Prolia | Denosumab | 34 | 29 |
| Restasis | Cyclosporine | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 28 |
| Bepotastine Besilate | Bepotastine Besilate | 31 | 11 |
| Valsartan | Valsartan | 31 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Eliquis | Apixaban | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 28 | suppressed |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | 11 |
| Nifedipine Er | Nifedipine | 25 | 11 |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 22 | suppressed |
| Potassium Chloride | Potassium Chloride | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 20 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 18 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 17 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | 15 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Cyclosporine | Cyclosporine | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Anastrozole | Anastrozole | 15 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Repaglinide | Repaglinide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Rifampin | Rifampin | 12 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Proctozone-Hc | Hydrocortisone | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $106.49 · 5 records | ABBVIE INC. | FARXIGA, OTEZLA, QULIPTA, REPATHA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error